CN101217973A - 使用第二代免疫调节寡核苷酸增强的hiv疫苗活性 - Google Patents

使用第二代免疫调节寡核苷酸增强的hiv疫苗活性 Download PDF

Info

Publication number
CN101217973A
CN101217973A CNA2005800079845A CN200580007984A CN101217973A CN 101217973 A CN101217973 A CN 101217973A CN A2005800079845 A CNA2005800079845 A CN A2005800079845A CN 200580007984 A CN200580007984 A CN 200580007984A CN 101217973 A CN101217973 A CN 101217973A
Authority
CN
China
Prior art keywords
hiv
antigen
immunogen
immunomodulatory oligonucleotide
mixed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800079845A
Other languages
English (en)
Chinese (zh)
Inventor
马里奥·克莱里西
理查德·巴塞洛缪
多萝西·布雷
埃卡姆巴·坎迪马拉
萨德希尔·阿格拉瓦尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immune Response Corp
Aceragen Inc
Original Assignee
Immune Response Corp
Hybridon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Response Corp, Hybridon Inc filed Critical Immune Response Corp
Publication of CN101217973A publication Critical patent/CN101217973A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2005800079845A 2004-03-12 2005-03-11 使用第二代免疫调节寡核苷酸增强的hiv疫苗活性 Pending CN101217973A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55287104P 2004-03-12 2004-03-12
US60/552,871 2004-03-12

Publications (1)

Publication Number Publication Date
CN101217973A true CN101217973A (zh) 2008-07-09

Family

ID=34994209

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800079845A Pending CN101217973A (zh) 2004-03-12 2005-03-11 使用第二代免疫调节寡核苷酸增强的hiv疫苗活性

Country Status (7)

Country Link
US (1) US20050266015A1 (https=)
EP (1) EP1729802A4 (https=)
JP (1) JP2008500963A (https=)
CN (1) CN101217973A (https=)
AU (1) AU2005222909B2 (https=)
CA (1) CA2557443A1 (https=)
WO (1) WO2005089231A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
CN1753687A (zh) 2002-10-29 2006-03-29 科勒制药集团股份有限公司 Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
US7470674B2 (en) * 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
PT2078080E (pt) 2006-09-27 2015-09-18 Coley Pharm Gmbh Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada
EP2575878B1 (en) * 2010-05-28 2018-06-13 Zoetis Belgium S.A. Vaccines comprising cholesterol and cpg as sole adjuvant-carrier molecules

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912332A (en) * 1996-07-26 1999-06-15 Hybridon, Inc. Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides
CA2512484A1 (en) * 2003-01-16 2004-05-08 Hybridon, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
MXPA06001996A (es) * 2003-08-28 2006-06-20 Immune Response Corp Inc Composiciones de hiv inmunogeneticas y metodos relacionados.

Also Published As

Publication number Publication date
EP1729802A4 (en) 2009-12-16
WO2005089231A2 (en) 2005-09-29
EP1729802A2 (en) 2006-12-13
JP2008500963A (ja) 2008-01-17
AU2005222909B2 (en) 2010-03-11
US20050266015A1 (en) 2005-12-01
WO2005089231A3 (en) 2007-12-06
AU2005222909A1 (en) 2005-09-29
CA2557443A1 (en) 2005-09-29

Similar Documents

Publication Publication Date Title
CA2372960C (en) Hiv immunogenic compositions and methods
US6737066B1 (en) HIV immunogenic compositions and methods
Sjölander et al. Immune responses to ISCOM® formulations in animal and primate models
EP1198249B1 (en) Use of cpg as an adjuvant for hiv vaccine
ES2240526T3 (es) Composicion farmaceutica para inmunizar contra el sida.
Mastelic et al. Mode of action of adjuvants: implications for vaccine safety and design
Dumais et al. Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge
NZ535148A (en) HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
Borsutzky et al. Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant
Fast et al. Human trials of experimental AIDS vaccines
Kommareddy et al. MF59: A safe and potent adjuvant for human use
AU2005222909B2 (en) Enhanced activity of HIV vaccine using a second generation immunomodulatory oligonucleotide
US20110142911A1 (en) HIV epitopes and pharmaceutical composition containing same
US20030044428A1 (en) Method for treating an HIV-infected individual by combining immunization with structured interruption of anti-retroviral treatment
US20070253979A1 (en) Immunogenic Hiv Compositions and Related Methods
HK1114789A (en) Enhanced activity of hiv vaccine using a second generation immunomodulatory oligonucleotide
CN102258779B (zh) 四种及四种以上hiv载体基因疫苗序贯及重复应用
US20090087456A1 (en) Adjuvanted vaccine
WO2024173143A2 (en) Vaccines incorporating hiv th/ctl epitope peptides to prevent and treat patients with hiv infection and aids
KR20070019635A (ko) 면역원성 ｈｉｖ 조성물 및 이와 관련된 방법
ZA200108559B (en) HIV immunogenic compositions and methods.
MXPA01010784A (en) Hiv immunogenic compositions and methods
SA02230071B1 (ar) تركيبات مولدة للمضاد ومساعدة تشمل فوسفات جلوكوز أمين أمينوالكيل و -il-12 أو csf gm-

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1114789

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080709

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1114789

Country of ref document: HK